Bill Enright
William “Bill” Enright joined Vaxin in June 2008 and currently serves as CEO. Prior to joining Vaxin, Mr. Enright spent six years with GenVec, Inc. with increasing responsibilities including the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including approximately $140M of funding for vaccine related initiatives and moving four vaccines into clinical development. Mr. Enright brings 20 years of experience in a variety of positions within the life science/biotech industry. Mr. Enright was a self-employed consultant, where he provided business development and strategic marketing services to academic institutions, and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc. (now Invitrogen), working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.

Kent R. Van Kampen, D.V.M., Ph.D.
COO and President, has been CEO of several biotechnology companies including Virogenetics, a Division of Aventis Pasteur, the largest vaccine company in the world. While leading Virogenetics, the Division created multiple recombinant vaccines that are currently licensed in the veterinary market. Dr. Van Kampen brings a wealth of experience in the field of vaccinology, especially in research, development and commercialization. Earlier in his career, Dr. Van Kampen was the Department Head of Veterinary Sciences at Utah State University and Director of Physiological Research at Medtronic. He serves on the Boards of Vaxin Inc., HMV Corp., ImmunoMed Corp. and The Van Kampen Group Inc.

De-chu Tang, Ph.D.
Vice President and Chief Technical Officer, is Vaxin’s Scientific Founder. He obtained his PhD in Microbiology at Indiana University and did postdoctoral work at Baylor College of Medicine, Duke University, and the University of Texas Southwestern Medical Center before he joined faculty at the University of Alabama at Birmingham and subsequently founded Vaxin Inc. Dr. Tang was one of the first to have developed DNA vaccines and noninvasive epicutaneous vaccines. In October 2000, Dr. Tang received the prestigious Wallace H. Coulter Award for innovation and entrepreneurship.

Timothy J. Segers, J.D.
Corporate Counsel and Secretary, is a Partner with Balch & Bingham LLP. He is a member of the firm's Corporate, Tax and Finance section and Technology Law Counselors practice group. He is engaged primarily in a corporate and tax practice for clients ranging from emerging growth companies to publicly-traded companies. Mr. Segers corporate practice includes the areas of mergers and acquisitions, securities, business planning and general corporate matters. His tax practice is focused primarily on the federal and state taxation of corporations, partnerships and other pass-through entities.

Michael J. Humber, C.P.A., M.B.A.
CFO and Treasurer, has been the CFO of three venture capital companies. Mr. Humber is also a principal at Redmont Venture Partners, where he focuses on internal and external financial reporting, investment analysis, and deal structuring. Earlier in his career, Mr. Humber worked in Birmingham, AL and New York, NY in the Financial Advisory Services division of PricewaterhouseCoopers, the largest accounting and professional services firm in the world. Mr. Humber is a Certified Public Accountant and received his Bachelor's of Science in Management from Tulane University and his Master's in Business Administration from Vanderbilt University.

Bill Enright
CEO - See Management Team above.

Kent Van Kampen, D.V.M., Ph.D.
COO and President - See Management Team above.

G. Michael Alder,
Member of the Board, former Chairman, and co-founder of Vaxin Inc. with Dr. Tang. Mr. Alder is a co-founder of Redmont Venture Partners and has over 30 years of experience in leading technology based start-up companies. He also served as Executive Director of the Biotechnology Association of Alabama and as CEO of Emerging Technology Partners from 1997 to 2003. Prior to coming to Alabama in 1994 he co-founded the Grow Utah Fund that focused on creating technology-based businesses. In 1989 he was asked by the Utah Governor to head the State's Office of Technology Development, which he did for 5 years as its Executive Director, helping bring Utah's Centers of Excellence programs to national prominence. In 1973 he founded NPI, a plant biotechnology company in Salt Lake City, Utah and served as President, COO and Vice Chairman of that company for 15 years as it grew to over 700 employees. He has recently returned to Utah to serve as Director of the Technology Transfer Office at Brigham Young University.

Jaap Goudsmit, M.D., Ph.D.
Member of the Board, also serves as Crucell's Chief Scientific Officer and is responsible for all of their R&D activities. He was their Senior Vice President of Vaccine Research from September 2001 till July 2002 and member of the management committee from July 2002 as Executive Vice President Vaccine R&D. Prior to joining Crucell, Dr. Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, and was Chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Dr. Goudsmit has also taught and been a fellow at a number of institutions, such as the National Institutes of Health and New York University. He was founding Chairman of the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI) and the founding Co-Chair of the European Vaccine Effort against HIV/AIDS (EuroVac). In July 2003, Dr. Goudsmit was appointed Chairman of the Board of the AIDS Foundation East-West, a NGO focused on AIDS prevention in the countries of the former Soviet Union. Since 1989 he has been a professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree and a PhD from the University of Amsterdam.

Philip L. Hodges
is a co-founder and Managing Director of Redmont Venture Partners, located in Birmingham, Alabama. Since 1997, Redmont has invested capital into early stage companies primarily in the healthcare and information technology sectors. His previous experience includes management positions at Atherotech, Tubular Products Corporation and HealthSouth. Mr. Hodges currently serves as a Director for the following companies: Allvivo, Entegreat, and Reliant Medical Products.

Stefan Gravenstein, M.D., M.P.H.
is Professor of Internal Medicine and Director of the Glennan Center for Geriatrics and Gerontology at Eastern Virginia Medical School. Dr. Gravenstein has broad clinical and basic research interests including vaccination, immune-senescence, and influenza in the elderly. He is a committee member of the National Campaign for Influenza Prevention, and past chair of the National Institute of Aging Clinical Aging Review Committee.

John Petricciani, M.D.
is Senior Vice President, Medical and Regulatory Affairs at CancerVax Corporation. From 1992-1997, Dr. Petricciani served as VP, Regulatory Affairs at Genetics Institute, Inc. Prior to that, Dr. Petricciani held senior positions in the public an private sectors, including the FDA from 1973-1985, where he served as Director of the Office of Biologics, and the NIH from 1968-1972.

Philip K. Russell, M.D.
is a Professor Emeritus at Johns Hopkins School of Hygiene and Public Health. Prior to joining the University in 1990, Dr. Russell served in the U.S. Army Medical Department where he pursued a career in infectious disease. He has been directly involved in the development of several vaccines including adenovirus, meningitis, hepatitis A, dengue, and Japanese encephalitis as well as biodefense vaccines. He has served on numerous boards and advisory committees for national and international agencies including several Institutes of Medicine committees. He has served as a Special Adviser in the Office of Public Health Emergency Preparedness, in the Office of the Secretary, Department of Health and Human Services since November 2001. He directed the development and acquisition of smallpox and anthrax vaccines for the Strategic National Stockpile.

Gerald Quinnan, M.D., Ph.D.
had a 20-year career with the Biological Section of the FDA culminating in his being the acting Head of CBER for 3 years. He is now Department Head of Infectious Diseases at the Uniformed Medical Colleges in Bethesda, Md.

Richard Whitley, M.D.
is Professor of Pediatrics and the Director of the Center for Biodefense and Emerging Infections at the University of Alabama at Birmingham. Dr. Whitley leads the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group whose role is to perform clinical trials of antiviral therapies. He has published over 260 articles and serves on numerous government advisory committees, including VERBAC (FDA Vaccine Advisory Committee) and the Board of Scientific Councilors for NIAID.